Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
Holding OCUL?
Track your performance easily
OCUL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.63 - $11.78
Previous Close$8.69
Volume1.03M
Average Volume (3M)1.18M
Market Cap
$1.37B
Enterprise Value$1.01B
Total Cash (Recent Filing)$427.22M
Total Debt (Recent Filing)$75.12M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Mar 06, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding157,217,427
10 Day Avg. Volume821,746
30 Day Avg. Volume1,177,045
Standard Deviation0.27
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)3.88
Price to Sales (P/S)22.24
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.51
Enterprise Value/Gross Profit19.08
Enterprise Value/Ebitda-6.58
Forecast
1Y Price Target
$17.83Price Target Upside98.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ocular Therapeutix News
PremiumCompany Announcements
Ocular Therapeutix Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe fast enrollment completion for SOL-1 reflects a strong demand for a durable treatment option for wet AMD.
Financial PerformanceThere is a strong cash position with $427.2M in cash at the end of September 2024.
Regulatory ApprovalThe FDA has given written approval that the SOL-R repeat-dosing non-inferiority study is acceptable for approval in wet AMD, which is seen as a positive development.
Bears Say
Clinical TrialsRisks include the failure of OTX-TKI or OTX-TIC in clinical trials.
Financial PerformanceTotal revenue was $15.4M, representing 2.3% year-over-year growth yet missing the projection of $16.8M.
Share DilutionRisks include potential dilution risk.
---
Ownership Overview
15.47% Insiders
9.94% Mutual Funds
56.72% Other Institutional Investors
5.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCUL FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $3.63 and its highest was $11.78 in the past 12 months.
What is Ocular Therapeutix’s market cap?
Currently, no data Available
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Mar 06, 2025 which is in 70 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Nov 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.023.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -$0.25.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 157,217,420 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went down -6.415%.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Among the largest hedge funds holding Ocular Therapeutix’s share is Perceptive Advisors LLC. It holds Ocular Therapeutix’s shares valued at 29M.
---
Ocular Therapeutix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.83 (98.55% Upside)
$17.83 (98.55% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $255.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.55%
12-Months-Change
Fundamentals
Return on Equity
-96.89%
Trailing 12-Months
Asset Growth
201.98%
Trailing 12-Months
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
---
OCUL Earnings Call
Q3 2024
0:00 / 0:00
---
OCUL Stock 12 Month Forecast
Average Price Target
$17.83
▲(98.55% Upside)
Technical Analysis
Best Analysts Covering OCUL
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+36.44%
reiterated a buy rating 23 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +36.44% per trade.
---